- Conditions
- 2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection, SARS-CoV-2 Infection, Respiratory Distress Syndrome, Adult, Adult Respiratory Distress Syndrome
- Interventions
- USB002, Placebo
- Drug
- Lead sponsor
- US Biotest, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–10
of 10
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV Clear all
- Conditions
- Acute Lung Injury, ALI, COVID-19
- Interventions
- RLS-0071 10 mg/kg, RLS-0071 40 mg/kg, Placebo
- Drug
- Lead sponsor
- ReAlta Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Moderate to Severe Acute Respiratory Distress Syndrome Associated With COVID-19
- Interventions
- Remestemcel-L
- Drug
- Lead sponsor
- Mesoblast International Sàrl
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
- Interventions
- Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
- Biological
- Lead sponsor
- Jeffrey Bluestone
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Columbus, Ohio
- Conditions
- COVID19, ARDS
- Interventions
- CK0802, Placebo
- Biological · Drug
- Lead sponsor
- Cellenkos, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 2 more
- Conditions
- Acute Respiratory Distress Syndrome, COVID-19
- Interventions
- Brexanolone, Placebo
- Drug
- Lead sponsor
- Sage Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- Fresno, California • Augusta, Georgia • Boston, Massachusetts + 6 more
- Conditions
- Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)
- Interventions
- Nezulcitinib (TD-0903) Dose A, Nezulcitinib (TD-0903) Dose B
- Drug
- Lead sponsor
- Theravance Biopharma
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- ARDS
- Interventions
- MultiStem, Placebo
- Biological
- Lead sponsor
- Healios K.K.
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Akron, Ohio • Cleveland, Ohio
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Syndrome Coronavirus 2, Sars-CoV2, Ards, Acute Respiratory Distress Syndrome
- Interventions
- APL-9, Vehicle Control
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 16
- States / cities
- Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more
- Conditions
- Acute Respiratory Distress Syndrome, Viral or Bacterial Infections, Pneumonia, Pneumonia, Viral, Respiratory Infection, COVID-19 Acute Respiratory Distress Syndrome
- Interventions
- AV-001 Injection, AV-001 Placebo Injection
- Drug
- Lead sponsor
- Vasomune Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Newport Beach, California • Denver, Colorado • Hyattsville, Maryland + 2 more